NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Lifevantage Corp. LFVN
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$228.5M
▲ 14.2% vs FY2023
EPS · FY24
$0.75
Dividend / sh · FY24
$0.17
Payout · FY24
21%
ROE · FY24
32.3%
Net margin · FY24
4.3%
Dividend coverage
4.5×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 228.5M
Revenue, FY2024 · full 15-year series below
Revenue
Net income
4 cents of every revenue dollar became profit this year.
Per share
USD 0.75
Diluted EPS, FY2024
EPS
Dividend
Earnings covered the dividend 4.5 times — the rest stayed in the company.
Profitability
32.3%
Return on equity, FY2024
ROE
Operating margin5.3%
Net margin4.3%
Return on assets14.8%
Each USD of equity produced 32 cents of profit this year.
Returned to shareholders
USD 5.2M
returned in FY2024 · dividends + net buybacks
Dividends paidUSD 2.1M
Net buybacksUSD 3.1M
Share of profit53.2%
Consecutive raises—
USD 2.1M in dividends and USD 3.1M in buybacks — 53% of the year's profit went back to shareholders.
Growth
−0.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.5%
−0.4%
+1.8%
Net income
+46.5%
−3.2%
+3.2%
EPS, diluted
+46.2%
−1.0%
+4.1%
Dividend / share
+76.5%
Returned to shareholders
−17.3%
−0.7%
−6.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years−13.2%
Change, 10 years−11.0%
The share count shrank 13% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 72.0M
total assets, end of FY2024
Total assetsUSD 72.0M
EquityUSD 34.6M
CashUSD 20.2M
Current ratio1.87×
Equity funds 48% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.1
0.0
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.1
EPS, diluted $
0.75
0.23
0.20
0.24
0.90
0.79
0.50
0.41
0.11
0.42
0.50
0.71
0.06
0.11
−0.69
Dividend / sh $
0.17
0.55
0.12
0.03
·
·
·
·
·
·
·
·
·
·
·
Payout %
21
236
62
12
0
0
·
·
·
·
·
·
·
·
·
ROE %
32.3
9.7
7.7
9.1
36.8
38.2
30.2
31.6
12.8
98.0
344.3
62.8
24.5
333.6
·
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.10
0.12
0.11
0.10
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
59 of 60
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed